This study uses existing health records and insurance claims data to understand how adults in the United States are treated with KarXT, a medication for schizophrenia. It will describe who receives KarXT, how it is used in real-world practice, and how often healthcare services such as hospital visits are used. It will also explore information recorded by clinicians about schizophrenia symptoms
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of all-cause and schizophrenia-related healthcare encounters per participant
Timeframe: Baseline and up to 6 months
Number of participants adherent to KarXT (proportion of days covered ≥80%)
Timeframe: Baseline and up to 6 months
Time to discontinuation of KarXT
Timeframe: Baseline and up to 6 months
KarXT initial dose (index dose)
Timeframe: Baseline
Number of of participants with dose increases or decreases
Timeframe: Baseline and up to 6 months
Number of participants using concomitant antipsychotic and anticholinergic medications
Timeframe: Baseline and up to 6 months
Number of participants with comorbidities
Timeframe: Baseline and up to 6 months
Number of participants with gastrointestinal adverse events
Timeframe: Baseline and up to 6 months
Number of participants with documented schizophrenia symptoms
Timeframe: Baseline and up to 6 months